comprehensive -WSS

comprehensive

author：entertainment 2025-09-05 18:28:32 - browse：93713

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： David Sabatini, ex

Wikipedia

hotspot

WSS

Surge of respiratory disease in China has likely explanation

Novo: Oral version of Ozempic leads to 15% weight loss

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Congress must reauthorize a committee to support older Americans

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Mom launches Girl Scout troop for LGBTQ youth in Texas

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Peter Hotez and the public health issue of online harassment

Xenotransplantation trials will require adjusting expectations, experts say

Apple is now the first public company to be valued at $3 trillion

Millions may soon lose Medicaid when they don't have to

The cancer drug shortage isn’t new — and neither are the solutions

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Medical leaders decry Supreme Court decision on affirmative action

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

At least 13 dead in Texas as scorching temps continue

Hospitals look to new technology to keep health care workers safe

focus

Astellas still sees hope in its gene therapy after four deaths

How to fix the rural physician shortage in the U.S.

Novo pauses ads for weight loss drug Wegovy amid demand

Altering the blood type of lungs raises potential for universal organs for transplants

FDA's Woodcock to retire early next year

Senate panel passes drug pricing bills, but drops one PBM reform

Wikipedia

hotspot

hotspot

hotspot